FreeStyle Libre

Search documents
美敦力任命新高管!糖尿病子公司上市准备提速
思宇MedTech· 2025-07-10 10:13
# 关于Chad Spooner 2025年5月,美敦力宣布计划将其糖尿病业务分拆为一家独立的、公开上市的公司,预计在 18个月内 完成分 离。MiniMed将继承美敦力在糖尿病管理领域的创新传统, 专注于提供完整的胰岛素管理系统,包括自动胰 岛素泵、连续血糖监测仪(CGM)和智能胰岛素笔等产品 。 2025年7月8日, Medtronic(美敦力) 宣布, Chad Spooner将于2025年7月14日起正式出任其糖尿病业 务部门 MiniMed 的首席财务官(CFO) 。此次任命正值Medtronic计划将糖尿病业务分拆为一家独立上市公 司之际,旨在为该业务板块的独立运营和未来发展奠定财务与战略基础。 Chad Spooner 拥有超过25年的财务领导经验,横跨医疗、消费品和工业领域,具备丰富的企业转型、财务 战略和资本市场运作经验。以下是其关键职业经历: 高管评价 BIC集团(BIC Group)CFO :在加入Medtronic之前,Spooner担任全球消费品公司BIC的 首席财务 官 ,负责全球财务战略、投资者关系及企业并购事务。 Tenex Capital Management :他曾联合创办 ...
Should You Buy Abbott Stock At $135?
Forbes· 2025-07-09 10:35
CANADA - 2025/04/03: In this photo illustration, the Abbott Laboratories logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the company’s solid quarterly results and positive future forecasts ...
2 Dividend Stocks to Buy for Decades of Passive Income
The Motley Fool· 2025-07-06 12:45
In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.25%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon.These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVieAbbVie is a pharmaceutical leader with a ...
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
ZACKS· 2025-07-02 15:06
Key Takeaways ABT posted strong Q1 CGM sales of over $1.7B, up 21.6% y/y, on FreeStyle Libre's global momentum. Diagnostics sales rose on growing demand for routine tests, with Core Lab up 6.5% outside China. EPD organic sales grew 8% as ABT scaled up its capital-light licensing model in emerging markets.Abbott’s (ABT) diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently.Factors Driving ABT SharesWithin Abbott’s ...
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
The Motley Fool· 2025-06-28 09:49
Core Viewpoint - The healthcare sector is positioned as a strong long-term investment opportunity, with a focus on companies that have shown adaptability and are well-prepared for future challenges [2]. Group 1: Abbott Laboratories - Abbott Laboratories, founded in 1888, has a market capitalization of $240 billion and offers diverse healthcare products across multiple sectors [4]. - The company is a leader in medical devices, diagnostics, nutritional products, and established pharmaceuticals, with notable products like the MitraClip and FreeStyle Libre [5][6]. - Abbott anticipates an 8% year-over-year revenue growth in 2025 and continues to innovate, recently receiving the European CE Mark for the Volt PFA System [7][8]. - Abbott has a strong dividend history, having increased its dividend for 53 consecutive years [8]. Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has a market capitalization of approximately $328 billion and generated $56.3 billion in sales last year [9][10]. - The company has successfully navigated the loss of U.S. exclusivity for its top product, Humira, by investing in R&D and acquisitions, leading to a robust product pipeline [11]. - AbbVie’s successors to Humira, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [12]. - AbbVie has increased its dividend by a cumulative 310% since its spin-off, with a forward dividend yield of 3.51% [12]. - The stock is considered relatively inexpensive, trading at 15.2 times forward earnings, with growth potential from new products [13].
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
ZACKS· 2025-06-23 14:51
Key Takeaways TNDM launched early U.S. access for t:slim X2 pump compatible with Abbott's FreeStyle Libre 3 Plus sensor. Abbott's Libre 3 Plus sends glucose data every minute to TNDM's t:slim mobile app. TNDM plans to integrate Abbott's future sensors for broader diabetes management solutions.Tandem Diabetes Care, Inc.’s (TNDM) t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) senso ...
DXCM's Access Gains and Operational Strength Offset Margin Pressures
ZACKS· 2025-06-20 14:26
Key Takeaways Dexcom saw record new patient starts and expanded T2D access coverage in Q1 2025. Dexcom's 15-day G7 and OTC Stelo drive innovation and support long-term commercial growth. Dexcom faces margin pressure from freight costs, inflation and an ongoing FDA warning letter.DexCom (DXCM) delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year progresses, several key growth ...
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
ZACKS· 2025-05-30 15:10
Core Insights - Abbott's diversified business portfolio is positioned for continued growth into 2025 despite foreign exchange challenges [1][7] - The company has seen significant growth in its Diagnostics and Diabetes Care segments, with a strong demand for routine diagnostics and continuous glucose monitoring systems [2][3][4] Business Performance - Abbott's Diagnostics business accounted for 20% of total revenues in Q1 2025, with a 6.5% growth in core laboratory diagnostics, excluding China [2] - The Diabetes Care segment reported sales exceeding $1.7 billion in Q1 2025, growing 21.6%, driven by the success of the FreeStyle Libre system [4] - Established Pharmaceuticals Division (EPD) sales increased 8% organically in Q1 2025, supported by a focus on biosimilars and a licensing model in emerging markets [5] Market Position - Year-to-date, Abbott's shares have gained 18.6%, outperforming the industry average of 5.2%, indicating strong market momentum [6] - Abbott's FreeStyle Libre has achieved global leadership in continuous glucose monitoring systems for both Type 1 and Type 2 diabetes users [3][4] Challenges - Foreign exchange fluctuations negatively impacted Abbott's sales by 2.8% year-over-year in Q1 2025, primarily due to a significant portion of revenues coming from international markets [7] - The company faces increased expenses related to raw materials and freight due to a challenging macroeconomic environment, which may affect future performance [8][9]
Abbott Stock Gains Following FDA Approval of the Tendyne System
ZACKS· 2025-05-28 14:25
Core Viewpoint - Abbott Laboratories has received FDA approval for its Tendyne transcatheter mitral valve replacement system, enhancing its Structural Heart portfolio and providing a minimally invasive solution for patients with severe mitral annular calcification [1][5][6]. Company Summary - Abbott's stock increased by 1.3% to $132.94 following the announcement of the Tendyne system approval [2]. - The company has a market capitalization of $231.29 billion and an earnings yield of 3.9%, significantly higher than the industry average of 0.6% [4]. - Abbott's Structural Heart division includes a diverse product range, such as MitraClip and TriClip, which positions the company favorably in the market [3]. Product Importance - The Tendyne system addresses mitral valve diseases caused by severe mitral annular calcification, offering a less invasive alternative for high-risk patients who may not be suitable for open-heart surgery [5]. - The system's innovative design allows for adaptability to various patient anatomies, with a self-expanding valve that can be repositioned during implantation [6]. Industry Prospects - The transcatheter mitral valve replacement market is expected to grow at a compound annual growth rate of 20% from 2025 to 2030, driven by the rising prevalence of mitral valve diseases and a preference for minimally invasive procedures [8]. Stock Performance - Over the past year, Abbott's shares have increased by 32%, outperforming the industry growth of 10.3% [11].
2 Dividend Stocks to Buy With $500 and Hold Forever
The Motley Fool· 2025-05-23 10:30
Core Viewpoint - The stock market has experienced volatility, but this does not deter investment, especially in resilient companies like Zoetis and Abbott Laboratories, which are strong candidates for income stocks [1][2]. Group 1: Zoetis - Zoetis is a leading animal health company with a diverse portfolio, including over 300 product lines, with about 15 generating over $100 million in annual revenue [4]. - Despite facing increased competition, particularly with its Apoquel product, Zoetis has consistently outperformed the industry in revenue growth and maintains a strong market position [5][7]. - The companion animal segment is a significant revenue driver, benefiting from changing consumer behavior where younger generations are increasingly spending on pet care [6]. - Long-term growth is supported by rising global demand for animal protein and Zoetis' established product lineup, despite short-term market challenges [7]. - Zoetis has a solid dividend profile, having increased payouts by 502% over the past decade, with a forward yield of 1.2% and a conservative cash payout ratio of 34.2% [8]. Group 2: Abbott Laboratories - Abbott Laboratories is diversified across medical devices, nutrition, diagnostics, and pharmaceuticals, which helps stabilize revenue during segment-specific challenges [9]. - The FreeStyle Libre continuous glucose monitoring system is a key growth driver, becoming the most successful medical device in dollar sales, with significant growth potential in an underpenetrated market [10]. - Demand for products like the MitraClip is expected to rise due to an aging population, positively impacting Abbott's overall results [11]. - Abbott has a strong income profile, having raised dividends for 53 consecutive years, with a yield of 1.8% and a cash payout ratio of 60.4% [12]. - Despite facing lawsuits and competitive pressures, Abbott's robust healthcare presence and innovative capabilities position it well for long-term performance [13].